A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

Running, not enrolling · Phase 4 · Has a placebo group

Conditions studied: SARS-CoV-2

In brief

The purpose of this study is to evaluate the efficacy and safety of mRNA-1283 and mRNA-1273 (variant formulations) in adults 50 to 64 years of age without high risk factors for severe COVID-19.

Key facts

Study ID
NCT07266558
Run by
ModernaTX, Inc.
People needed
30000
Starts
2025-11-26
Expected to finish
2027-06-16
Last updated by the study team
2026-04-28

Who can join

Age: 50 and older, up to 64. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.